135 related articles for article (PubMed ID: 2782476)
1. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients.
Lin KM; Poland RE; Nuccio I; Matsuda K; Hathuc N; Su TP; Fu P
Am J Psychiatry; 1989 Oct; 146(10):1307-11. PubMed ID: 2782476
[TBL] [Abstract][Full Text] [Related]
2. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
[TBL] [Abstract][Full Text] [Related]
3. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
[TBL] [Abstract][Full Text] [Related]
4. The relationship between plasma haloperidol concentrations and clinical results.
Palao DJ; Araúxo A; Haro JM; Brunet M; Bernardo M
Arch Gen Psychiatry; 1996 Dec; 53(12):1167-9. PubMed ID: 8956684
[No Abstract] [Full Text] [Related]
5. The interpretation of plasma haloperidol concentrations.
Kirch DG; Bigelow LB; Wyatt RJ
Arch Gen Psychiatry; 1985 Aug; 42(8):838-40. PubMed ID: 4015329
[No Abstract] [Full Text] [Related]
6. Dosing the antipsychotic medication olanzapine.
Nemeroff CB
J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
[TBL] [Abstract][Full Text] [Related]
7. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.
McEvoy JP; Hogarty GE; Steingard S
Arch Gen Psychiatry; 1991 Aug; 48(8):739-45. PubMed ID: 1883257
[TBL] [Abstract][Full Text] [Related]
8. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
[TBL] [Abstract][Full Text] [Related]
9. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
Marder SR; Davis JM; Chouinard G
J Clin Psychiatry; 1997 Dec; 58(12):538-46. PubMed ID: 9448657
[TBL] [Abstract][Full Text] [Related]
10. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
[TBL] [Abstract][Full Text] [Related]
11. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
Hollister LE; Kim DY
Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
[TBL] [Abstract][Full Text] [Related]
12. Plasma haloperidol levels: clinical response and fancy mathematics.
Van Putten T; Marder SR; Mintz J
Arch Gen Psychiatry; 1985 Aug; 42(8):835-8. PubMed ID: 4015328
[No Abstract] [Full Text] [Related]
13. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
15. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
[TBL] [Abstract][Full Text] [Related]
16. Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia.
Rao VA; Bishop M; Coppen A
Br J Psychiatry; 1980 Dec; 137():518-21. PubMed ID: 7214106
[TBL] [Abstract][Full Text] [Related]
17. Haloperidol concentrations elevated in Chinese patients.
Potkin SG; Shen Y; Pardes H; Phelps BH; Zhou D; Shu L; Korpi E; Wyatt RJ
Psychiatry Res; 1984 Jun; 12(2):167-72. PubMed ID: 6591221
[TBL] [Abstract][Full Text] [Related]
18. Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients.
Jann MW; Chang WH; Davis CM; Chen TY; Deng HC; Lung FW; Ereshefsky L; Saklad SR; Richards AL
Psychiatry Res; 1989 Oct; 30(1):45-52. PubMed ID: 2594870
[TBL] [Abstract][Full Text] [Related]
19. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
[TBL] [Abstract][Full Text] [Related]
20. Haloperidol: therapeutic window in schizophrenia.
Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
